Eureka Therapeutics to Present at Two Upcoming Virtual Conferences

Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced that it will participate virtually in two upcoming conferences in October:

• TCR-based Therapies Summit
  Title: ARTEMIS^® Antibody TCR T Cell Therapies for Solid Tumors
  Speaker: Cheng Liu, Ph.D., President and CEO
  Date: Tuesday, October 27, 2020
  Time: 9:00 a.m. EST

• Cell & Gene Therapy Bioprocessing & Commercialization
  Title: Optimizing Viral Vector Production
  Speaker: Nicole Nunez, Ph.D., Process Development Scientist
  Date: Thursday, October 22, 2020
  Time: 8:00 a.m. EST

ABOUT EUREKA THERAPEUTICS, INC.

Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company focused on developing novel T cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS^® cell receptor platform and E-ALPHA^® antibody discovery platform for the discovery and development of potentially safer and more effective T cell therapies for the treatment of solid tumors and hematologic malignancies. ET140203, the Company's lead asset, is currently in a Phase I/II US multicenter clinical trial in patients with advanced hepatocellular carcinoma (HCC).

Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com.